Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis. [electronic resource]
Producer: 19970320Description: 91-9 p. digitalISSN:- 0022-510X
- Antibodies -- blood
- Antigens, Surface -- metabolism
- Antineoplastic Agents -- administration & dosage
- Cells, Cultured -- chemistry
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Histocompatibility Antigens Class II -- metabolism
- Humans
- Immunoglobulin G -- biosynthesis
- Immunophenotyping
- Interferon alpha-2
- Interferon-alpha -- administration & dosage
- Lymphocytes -- cytology
- Lymphokines -- biosynthesis
- Macrophages -- chemistry
- Male
- Multiple Sclerosis -- drug therapy
- Neutralization Tests
- Pilot Projects
- Placebos
- Recombinant Proteins -- administration & dosage
- beta 2-Microglobulin -- metabolism
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.